Michael D. Pickard
About
Michael D. Pickard is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Michael D. Pickard has authored 38 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 21 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael D. Pickard's work include Melanoma and MAPK Pathways (15 papers), Colorectal Cancer Treatments and Studies (11 papers) and Ubiquitin and proteasome pathways (10 papers). Michael D. Pickard is often cited by papers focused on Melanoma and MAPK Pathways (15 papers), Colorectal Cancer Treatments and Studies (11 papers) and Ubiquitin and proteasome pathways (10 papers). Michael D. Pickard collaborates with scholars based in United States, Italy and Spain. Michael D. Pickard's co-authors include Paolo A. Ascierto, Reinhard Dummer, Caroline Robert, Mario Mandalà, Dirk Schadendorf, Keith T. Flaherty, Claus Garbe, Helen Gogas, Gabriella Liszkay and Carmen Loquai and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.
In The Last Decade
Michael D. Pickard
36 papers receiving 2.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Michael D. Pickard United States | 18 | 1.6k | 1.3k | 311 | 224 | 215 | 38 | 2.2k | ||
| Frank Wu United States | 15 | 1.3k 0.8× | 998 0.8× | 190 0.6× | 169 0.8× | 286 1.3× | 39 | 2.0k | ||
| Ilsung Chang United States | 16 | 2.1k 1.3× | 1.6k 1.2× | 281 0.9× | 199 0.9× | 228 1.1× | 34 | 2.7k | ||
| Laurie Sherman United States | 15 | 1.2k 0.8× | 1.0k 0.8× | 173 0.6× | 188 0.8× | 474 2.2× | 41 | 1.9k | ||
| Victor Sandor United States | 20 | 2.0k 1.3× | 1.7k 1.3× | 344 1.1× | 251 1.1× | 285 1.3× | 35 | 3.2k | ||
| Jeff Sosman United States | 20 | 1.2k 0.7× | 1.2k 0.9× | 498 1.6× | 278 1.2× | 301 1.4× | 38 | 2.2k | ||
| Jan Willem B. de Groot Netherlands | 27 | 1.5k 0.9× | 1.9k 1.5× | 348 1.1× | 241 1.1× | 367 1.7× | 94 | 3.2k | ||
| Ivana Krajsová Czechia | 16 | 1.5k 0.9× | 1.4k 1.1× | 243 0.8× | 118 0.5× | 213 1.0× | 40 | 1.9k | ||
| Peter F. Lebowitz United States | 24 | 2.3k 1.4× | 1.8k 1.4× | 141 0.5× | 422 1.9× | 411 1.9× | 40 | 3.2k | ||
| Luna Musib United States | 24 | 1.4k 0.9× | 952 0.7× | 104 0.3× | 342 1.5× | 483 2.2× | 77 | 2.6k | ||
| Emma Dean United Kingdom | 29 | 1.8k 1.1× | 1.4k 1.1× | 256 0.8× | 436 1.9× | 390 1.8× | 132 | 2.7k |
Countries citing papers authored by Michael D. Pickard
Since
Specialization
Citations
This map shows the geographic impact of Michael D. Pickard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael D. Pickard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael D. Pickard more than expected).
Fields of papers citing papers by Michael D. Pickard
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michael D. Pickard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael D. Pickard. The network helps show where Michael D. Pickard may publish in the future.
Co-authorship network of co-authors of Michael D. Pickard
This figure shows the co-authorship network connecting the top 25 collaborators of Michael D. Pickard. A scholar is included among the top collaborators of Michael D. Pickard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael D. Pickard. Michael D. Pickard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Pickard, Michael D., et al.. (2025). Axillary Management in Breast Cancer Patients with Positive Lymph Nodes Following Neoadjuvant Chemotherapy. Annals of Surgical Oncology. 33(3). 2298–2305.
2.
Sullivan, Ryan J., Jeffrey S. Weber, Sapna P. Patel, et al.. (2020). A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K -mutant Solid Tumors. Clinical Cancer Research. 26(19). 5102–5112.
3.
Kopetz, Scott, Axel Grothey, Eric Van Cutsem, et al.. (2020). Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. Journal of Clinical Oncology. 38(15_suppl). 4039–4039.
4.
Ascierto, Paolo A., Reinhard Dummer, Helen Gogas, et al.. (2020). Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma. European Journal of Cancer. 126. 33–44.
5.
Gogas, Helen, Keith T. Flaherty, Reinhard Dummer, et al.. (2019). Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. European Journal of Cancer. 119. 97–106.
6.
Dummer, Reinhard, Paolo A. Ascierto, Helen Gogas, et al.. (2018). Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. 19(10). 1315–1327.
7.
Dummer, Reinhard, Paolo A. Ascierto, Helen Gogas, et al.. (2018). Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology. 19(5). 603–615.
8.
Dummer, Reinhard, Paolo A. Ascierto, Helen Gogas, et al.. (2017). Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma. Annals of Oncology. 28. v429–v430.
9.
Gogas, Helen, Reinhard Dummer, Paolo A. Ascierto, et al.. (2017). Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma. Annals of Oncology. 28. v442–v442.
10.
Arance, Ana, Reinhard Dummer, Paolo A. Ascierto, et al.. (2017). Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma. Annals of Oncology. 28. v441–v441.
11.
Bhatia, Shailender, Anna C. Pavlick, Peter D. Boasberg, et al.. (2016). A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. Investigational New Drugs. 34(4). 439–449.
12.
Sarantopoulos, John, Geoffrey I. Shapiro, Roger B. Cohen, et al.. (2015). Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(4). 847–857.
13.
Garcia, Khristofer, Jonathan L. Blank, David C. Bouck, et al.. (2014). Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways. Molecular Cancer Therapeutics. 13(6). 1625–1635.
14.
Goy, André, Steven H. Bernstein, Alice McDonald, et al.. (2010). Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leukemia & lymphoma. 51(7). 1269–1277.
15.
Venkatakrishnan, Karthik, Michael D. Pickard, & Lisa L. von Moltke. (2010). A Quantitative Framework and Strategies for Management and Evaluation of Metabolic Drug-Drug Interactions in Oncology Drug Development. Clinical Pharmacokinetics. 49(11). 703–727.
16.
Swords, Ronan, Harry P. Erba, Daniel J. DeAngelo, et al.. (2010). The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study. Blood. 116(21). 658–658.
17.
Pickard, Michael D., et al.. (2007). Follow up of patients with colorectal polyps: are the BSG guidelines being adhered to?. Colorectal Disease. 9(3). 203–206.
18.
Goy, André, Steven H. Bernstein, Alice McDonald, et al.. (2007). Immunohistochemical Analyses for Potential Biomarkers of Bortezomib Activity in Mantle Cell Lymphoma from the PINNACLE Phase 2 Trial.. Blood. 110(11). 2573–2573.
19.
Lora, José M., Amal Al‐Garawi, Michael D. Pickard, et al.. (2003). FcεRI-dependent gene expression in human mast cells is differentially controlled by T helper type 2 cytokines. Journal of Allergy and Clinical Immunology. 112(6). 1119–1126.
20.
Grant, Ethan, Michael D. Pickard, Michael Briskin, & José-Carlos Gutierrez-Ramos. (2002). Gene expression profiles: Creating new perspectives in arthritis research. Arthritis & Rheumatism. 46(4). 874–884.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Frank Wu Breakdown of academic impact, for papers by Ilsung Chang Breakdown of academic impact, for papers by Laurie Sherman Breakdown of academic impact, for papers by Victor Sandor Breakdown of academic impact, for papers by Jeff Sosman Breakdown of academic impact, for papers by Jan Willem B. de Groot Breakdown of academic impact, for papers by Ivana Krajsová Breakdown of academic impact, for papers by Peter F. Lebowitz Breakdown of academic impact, for papers by Luna Musib Breakdown of academic impact, for papers by Emma Dean